Conventional mRNA Vaccines

The advantages of mRNA vaccines include high potency, rapid development, safe administration, and low-cost manufacturing, representing a promising alternative to conventional vaccine approaches. For vaccines, the investment of time and cost are important reference factors, profoundly guiding the development and manufacturing processes. Since mRNA vaccines' manufacturing processes are independent of encoded antigens, different vaccines can be produced on the same platform using the same production, purification methods, and manufacturing facilities. Based on an excellent team of scientists and advanced manufacturing facilities, Creative Biogene has the capability to support the one- stop service for conventional mRNA vaccines manufacturing. Our mRNA vaccine manufacturing is flexible, reproducible, and target-oriented, which can be used to produce safe, efficient, and highly immunogenic vaccines.

Schematic Illustration of mRNA Vaccine Production. Fig.1 Schematic Illustration of mRNA Vaccine Production. (Maruggi, G., et al, 2019)

Conventional mRNA vaccines

Two forms of mRNA vaccines have been developed, including conventional mRNA vaccines and self-amplifying mRNA vaccines. Conventional mRNA vaccines, also known as non-replicating mRNA vaccines, contain an ORF for encoding the antigen of interest, flanked by untranslated regions (5' and 3' UTRs) and with a terminal 5' cap and poly(A) tail structure. The vaccines drive transient antigen expressions after transfection. In addition, according to different delivery methods, the non-replicating mRNA vaccines can be further distinguished as dendritic cell mRNA vaccines and direct injection of non-replicating mRNA vaccines. Much progress has been made in the later vaccine format. It is cost-effective, and its administration is simple.

Service offering

Dendritic cell mRNA vaccines

Dendritic cells (DCs) are the most potent antigen-presenting cells of the immune system and are highly amenable to mRNA transfection, representing an attractive target for transfection by mRNA vaccines, both in vivo and ex vivo. mRNAs are first loaded into DCs ex vivo, and delivered to the body by re-infusion of the transfected cells. Dendritic cell mRNA vaccines allow precise control of the cellular target and efficient transfection. They are suitable for generating cell-mediated immunity against cancer. However, as a form of cell therapy, it is an expensive approach to vaccination.

Direct injection of non-replicating mRNA vaccines

Directly injectable, non-replicating mRNA vaccines are an attractive vaccine format due to their simple and economical administration, especially in resource-limited conditions. As a leading customized service provider in mRNA-based drug discovery and development, we provide a series of mRNA optimization services, involving the 5' cap, the poly(A) tail, 5' and 3' UTRs, and the coding region modification. We also offer multiple nanotechnologies to improve mRNA vaccine delivery, such as lipid-based and polymeric systems. For more details, please see our mRNA delivery vector service.

Creative Biogene is passionate about strong customer orientation and high-quality service. We continuously challenge ourselves to stay ahead and remain one of the leading mRNA-based drug R&D service providers worldwide. If you are interested in our services, please contact us for more information.


  1. Maruggi, G., et al. (2019). "mRNA as a transformative technology for vaccine development to control infectious diseases." Molecular Therapy, 27(4), 757-772.
  2. Jackson, N. A., et al. (2020). "The promise of mRNA vaccines: A biotech and industrial perspective." npj Vaccines, 5(1), 1-6.
For research use only. Not intended for any clinical use.
Offer for you
Online inquiry
Copyright © 2024 Creative Biogene. All rights reserved.